FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid buildup.
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing' Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma Three new cancer drugs could help make a dent in the company's ambitious plans for 2030.
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients over 96 weeks.
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi.
